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Abstract
Background: Reduction of blood flow is important in the induction of neurogenic intermittent
claudication (NIC) in lumbar spinal canal stenosis. PGE1 improves the mean walking distance in
patients with NIC type cauda equina compression. PGE1 derivate might be effective in dilating blood
vessels and improving blood flow in nerve roots with chronically compressed cauda equina. The
aim of this study was to assess whether PGE1 derivate has vasodilatory effects on both arteries and
veins in a canine model of chronic cauda equina compression.
Methods: Fourteen dogs were used in this study. A plastic balloon inflated to 10 mmHg was placed
under the lamina of the 7th lumbar vertebra for 1 week. OP-1206-cyclodextrin clathrate (OP-
1206-CD: prostaglandin E1 derivate) was administered orally. The blood vessels of the second or
third sacral nerve root were identified using a specially designed surgical microscope equipped with
a video camera. The diameter of the blood vessels was measured on video-recordings every 15
minutes until 90 minutes after the administration of the PGE1 derivate.
Results: We observed seven arteries and seven veins. The diameter and blood flow of the arteries
was significantly increased compared with the veins at both 60 and 75 minutes after administration
of the PGE1 derivate (p < 0.05). Blood flow velocity did not change over 90 minutes in either the
arteries or veins.
Discussion: The PGE1 derivate improved blood flow in the arteries but did not induce blood stasis
in the veins. Our results suggest that the PGE1 derivate might be a potential therapeutic agent, as
it improved blood flow in the nerve roots in a canine model of chronic cauda equina compression.
Background
Compression of the cauda equina by spinal stenosis is a
major clinical problem associated with neurogenic inter-
mittent claudication (NIC). A reduction in blood flow is
considered an important factor in inducing NIC in lum-
bar spinal canal stenosis [1-5], and improving blood flow
is expected to prevent NIC and leg symptoms. PGE1 leads
to vasodilation in both arterioles and venules [6]. In
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patients with NIC type cauda equina compression, intra-
venous PGE1 has been shown to improve mean walking
distance [1]. During myeloscopic observation of lumbar
spinal canal stenosis, blood vessels on the cauda equina
have been shown to dilate during NIC; thus microcircula-
tory disturbance of vessels on the cauda equina may play
an important role in NIC [7]. In addition, as seen on mye-
loscopic examination, dilation of vessels is observed after
administration of Lipo PGE1 in patients with lumbar spi-
nal stenosis [8]. However, even if vasodilatory effects are
achieved in both arteries and veins, it would lead to blood
stasis, which may subsequently induce a reduction in
blood flow. In the experimental study of the porcine
cauda equina compression, blood flow in veins on spinal
nerve is stopped by lower compression pressure than the
one in arteries [4]. Therefore, it is important to investigate
not only changes in the diameter of blood vessels but also
changes in blood flow in both arteries and veins in the
same model. The aim of this study was to assess the effect
of a PGE1 derivate on nerve blood flow in both arteries
and veins in a canine model of chronic cauda equina com-
pression.
Methods
A total of 14 dogs (average body weight 11.1 ± 0.4 kg)
were used in this study. The experimental protocol was
approved by the local animal ethics committee and con-
formed to Fukushima Medical University Guidelines, the
Japanese Government Animal Protection and Manage-
ment Law (No. 15), and the Japanese Government Notifi-
cation on Feeding and Safekeeping of Animals (No. 6). All
dogs were anesthetized with an intramuscular injection of
25 mg/kg ketamine hydrochloride (50 mg/ml Ketalar,
Parke-Davis, Morris Plains, New Jersey) and 10 mg/kg
pentobarbital sodium (50 mg/ml Nembutal, Abbott Lab-
oratories, North Chicago, Illinois). After endotracheal
intubation, anesthesia was maintained by inhalation of
nitrous oxide (3 l/min), oxygen (3 l/min), and halothane
(1%, SIC Chemicals Ltd, Bristol England).
Chronic cauda equina compression model [9-12]
The dogs were placed prone, and a partial laminectomy of
the caudal part of the sixth and seventh lumbar vertebras
was performed. Compression balloons were made by
welding thin polyethylene sheaths together. The width of
the balloon was 20 mm. The balloon was folded into
three layers and gently placed under the lamina of the sev-
enth lumbar vertebra. An ATS-1000 compressed-air sys-
tem (Aspen Laboratories, Littleton, Colorado) was used to
infuse a substance called "konnyaku" into the balloon at
a slow rate of 10 mmHg infusion pressure. This was based
on a clinical study that showed that epidural pressure at
the stenotic level is approximately 10 mmHg in spinal ste-
nosis patients in the prone position [13]. Konnyaku,
which is starch from the plant Amorphophalus rivieri,
becomes liquid after being mixed with water. Water at
room temperature was sufficient for konnyaku to become
viscous, which occurred in approximately 10 minutes.
There was no injury to the nerve tissue when the kon-
nyaku in the balloon became viscous. When there was no
further flow of konnyaku into the balloon, the infusion
pressure was maintained for 30 minutes to compensate
for the pressure loss caused by displacement of the tissues
in the spinal canal. The diameter of each balloon exceeded
that of the spinal canal and a reliable pressure transmis-
sion was provided to the cauda equina, as confirmed in
separate calibration experiments. The inflated balloon,
still under infusion, was then ligated at the carnial and
caudal borders of the lamina of the seventh lumbar verte-
bra. Parts of the balloon located dorsally to the lamina
were cut and removed. The balloon was then secured in
place between the cauda equina and the lamina of the sev-
enth lumbar vertebra.
One week after this procedure, 3 μg/kg with 10 ml normal
saline OP-1206 OP-1206α-CD cyclodextrin clathrate
(OP-1206α-CD), a prostaglandin E1 derivative, was
administrated orally and the studies described below were
performed. Dosing was based on the following findings of
other studies: Ninety to 95% of OP-1206 a-CD is
absorbed through the stomach in a rat, and the half-life of
this drug is 7 hours [14]. There are no data regarding
absorption rates in a canine model. In the clinical setting,
oral therapy with 15 to 30 μg per day OP1206 a-CD is
used for an adult patient. In rat studies [15,16], oral
administration of 30–300 μg/kg OP-1206α-CD has been
used; however, these concentrations are higher than those
used in the clinical setting. In a rat model, the blood con-
centration of OP1206α-CD is approximately 2 to 2.5% of
the total amount of drug administered. In a previous
canine model, 3–30 ng/kg/min OP-1206α-CD was
administered intravenously [17]. According to the clinical
setting, 30 μg was chosen orally in this study. Because the
mean weight of dogs in this study was 11.1 kg, 3 μg/kg
OP-1206α-CD was chosen as the best dose.
Studies were conducted 1 week after the initial operation
for the model construction, applying the same surgical
procedures (e.g., animal posture and anesthesia) as the
initial operation.
For application of OP-1206α-CD, a silicon tube was
inserted and placed in the stomach. A catheter was
inserted and placed in the left cervical artery for continu-
ous monitoring of blood pressure. Another catheter,
which was used for injection of ink, was inserted and
placed in the abdominal aorta from the right femoral
artery. In the preliminary experimental test, we had inves-
tigated the relationship among the location of the catheter
tip, the branch of the lumbar artery, and the ribs usingBMC Musculoskeletal Disorders 2008, 9:41 http://www.biomedcentral.com/1471-2474/9/41
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photofluorography. This test showed that the catheter was
between the first and third lumbar arteries when its tip
was placed on the same level as the distal bone edge of the
twelfth rib. Therefore, the catheter tip was placed around
the branch between the first and third lumbar arteries in
this study. After insertion of the catheters, the dogs were
placed prone. The lamina of the first and second sacral
vertebras, and ligamentum flavum between the laminas of
the seventh lumbar and first sacral vertebras were
removed, and the cauda equina was exposed. The second
or third sacral nerve root was identified just caudal to the
compression site. The blood vessels were observed using a
microscope equipped with a video-camera (Digital HI-
SCOPE Video System, Hirox Co. Ltd., Tokyo, Japan) at
400× magnification. From the catheter in the abdominal
aorta, 3 ml of blue ink (Pilot Co. Ltd., Tokyo, Japan) was
injected manually for 1 second. When the ink flowed
through the observed blood vessel, the color of the vessel
changed from red to blue for several seconds. After check-
ing the flow of ink from the catheter to the observed blood
vessels, we started to record the blood vessels before and
until 90 minutes after oral injection of OP-1206α-CD.
Before and every 15 minutes until 90 minutes after
administration of the drug, 3 ml of blue ink was injected
through the catheter. In the preliminary test, blue ink
flowed less than 5 seconds through an artery and longer
than 5 seconds through a vein. Therefore, the blood ves-
sels were divided into an artery and a vein according to
phases of ink appearance. After these procedures, the
measurements of diameter, blood flow velocity, and
blood flow volume index in observed blood vessels were
performed by an investigator in a blinded fashion using
video recordings. The diameter of the blood vessels (μm)
was measured three times for each ink injection using a
monitor-connected video system equipped with a dis-
tance measuring device (Fig. 1). Blood flow velocity (mil-
limeters per second) and time (seconds) of the color
changes from red to blue were calculated using iMovie
(Macintosh version) installed in a computer (Fig. 2).
Blood flow volume index was defined as (1/2 diameter)2
×(the blood flow velocity), to assess the changes in blood
flow volume for each observed vessels [9,18,19]. The val-
ues of diameter and blood flow volume index before
injecting OP-1206α-CD served as baseline values (100%).
All recordings of diameter and blood flow volume index
were expressed as a percentage of baseline values.
Statistical analysis
Comparisons of the difference in diameters of the blood
vessels and blood flow index among each group were per-
formed by repeated measure ANOVA. P values of less than
0.05 were considered significant. Intra-observer reliability
(R) was evaluated by one-way ANOVA. R values of more
than 0.8 were considered to be "good" and more than 0.9
be "excellent". The R value was more than 0.9 in all
groups; thus, the average data of each time point was used
for the graphs.
Results
Throughout the observation period, neither paralysis nor
bladder dysfunction was observed in any dog. There was
no wound infection. At the second operation, all balloons
were found to be intact in the inserted position. The blood
pressure did not change significantly before or after
administration of OP-1206α-CD. A total of 14 blood ves-
sels were observed (7 arteries and 7 veins).
The picture of nerve roots and blood vessels Figure 1
The picture of nerve roots and blood vessels. The blood vessel observed on the monitor. N: nerve root, B: blood vessel. 
Bar 100 μm.BMC Musculoskeletal Disorders 2008, 9:41 http://www.biomedcentral.com/1471-2474/9/41
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1) Diameter of blood vessels
The diameter of arteries, but not veins, dilated gradually.
There was a significant difference in the diameter of the
arteries at 60 and 75 minutes after administration of OP-
1206α-CD compared with the diameter of the veins (p <
0.05) (Fig. 3).
2) Blood flow velocity
Blood flow velocity did not change after administration of
OP-1206α-CD (Fig. 4). There was no significant differ-
ence between arteries and veins in velocity for 90 minutes.
3) Blood flow index
The blood flow index in the arteries but not the veins was
increased over 90 minutes with a significant difference
between groups at 60, 75, and 90 minutes (p < 0.05) (Fig.
5).
Discussion
NIC is a characteristic symptom among patients with lum-
bar spinal canal stenosis. It is aggravated by walking and
leads to reductions in walking distance. Reduced
intraneural blood flow is one cause of NIC [3,7]. Admin-
istration of PGE1  derivate and calcitonin, which are
thought to improve blood flow, has been reported to
improve walking distance of patients with NIC [1,20].
Intravenous administration of PGE1 increases nerve root
blood flow velocity after lumbar diskectomy in spinal ste-
nosis patients [21]. Experimental studies of PGE1 treat-
ments have also been reported. Compression of cauda
equina reduced blood flow in spinal nerve roots [4,5] and
PGE1 increased blood flow and prevented the reduction in
nerve conduction velocity in acute cauda equina compres-
sion [17]. In addition, intravenous injection of PGE1
derivative increased blood flow in chronic cauda equina
compression [9]. In this study, the diameter of the arteries,
but not the veins, increased after administration of PGE1
derivative under cauda equina compression. In addition,
blood flow in the arteries increased after administration of
PGE1 derivative. These results suggest that the PGE1 deriv-
ative has a vasodilatory effect and increases blood flow in
arteries. No changes in blood pressure were observed fol-
lowing administration of the PGE1 derivate, and blood
flow velocity was maintained during vasodilation. These
findings indicate that the vasodilatory effect of the PGE1
derivate on arteries enables increased blood flow without
inducing blood stasis. In veins, the PGE1 derivate did not
cause vasodilation or increases in blood flow. In clinical
practice, PGE1 derivative will be given orally or as an intra-
venous bolus. In the present study, PGE1 derivative was
administrated orally and the duration of the vasodilatory
effect was 90 minutes. In this experimental setting, it was
difficult to investigate the duration of the effect of the
PGE1  derivative after oral administration; however,
because the half-life of this drug is 7 hours through the
stomach in a rat and the increased of vasodilatation was
approximately 9% at 90 minutes, we can assume that the
duration of vasodilatation was more than 90 minutes in
this model.
The actions of PGE1 are mediated primarily by the IP
receptor, and include a vasodilatory effect as well as a
platelet aggregation inhibition effect mediated by PGI2.
The IP receptor is expressed in smooth muscle cells of var-
ious organs such as the aorta, coronary arteries, pulmo-
nary arteries, and cerebral arteries, whereas no expression 
Measurement of blood flow velocity Figure 2
Measurement of blood flow velocity. Time (seconds) was measured using ink color changes (t'-t). The distance from A to 
B was 0.82 mm. The blood flow velocity (mm/sec) was calculated by the formula shown.
Direction of blood flow time
t
t'
AB
vessel
vessel
Blood flow velocity (mm/sec)distance(B-A)/ t’-t(timeBMC Musculoskeletal Disorders 2008, 9:41 http://www.biomedcentral.com/1471-2474/9/41
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Changes of blood flow velocity Figure 4
Changes of blood flow velocity. There was no significant difference in arteries and veins in blood flow velocity over 90 min-
utes.
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Changes of the diameter Figure 3
Changes of the diameter. There was a significant difference in the diameter of arteries compared with veins at 60 and 75 
minutes after administration of OP-1206α-CD (p < 0.05).
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is found in veins [22]. However, PGE1 is known to dilate
both arterioles and venules [6]. In addition, cyclic GMP is
associated with smooth muscle relaxation, which is a dif-
ferent mechanism of vasodilation mediated by the IP
receptor [23]. PGE1 also inhibits aggregation of platelets
[24] and increases peripheral venous pressure [25] in
experimental studies. In a clinical study, PGE1 administra-
tion at a low infusion rate of 0.02 μg/kg/min increased
cardiac output without altering mean arterial blood pres-
sure and blood volume [26]. In a canine model, from 3.8
to 5.6 ng/kg/min PGE1 intravenously did not influence
systemic mean arterial pressure. Therefore, PGE1  may
change arterial blood flow in the nerve roots due to both
primary and secondary effects.
In this study, the arteries reacted to the administration of
PGE1 derivative whereas the veins did not. However, one
limitation of this study was that the changes in the diam-
eter and blood flow in arteries and veins were observed for
only 90 minutes. Another limitation of this study was that
walking capacity could not be investigated before and
after administration of the PGE1 derivative. However, in a
rat model, orally administered PGE1 improved walking
dysfunction and blood flow [16]. The increase of nerve
root blood flow may improve function of the nerve root
and lead to an improvement in walking capacity. Accord-
ing to the previous clinical reports, PGE1 derivative may
be a potential therapeutic agent for lumbar spinal stenosis
with NIC.
Conclusion
The PGE1 derivate may have effects of vasodilation on
arteries and improve blood flow of nerve roots in chronic
cauda equina compression.
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Changes of blood flow index Figure 5
Changes of blood flow index. The blood flow index in the arteries increased significantly at 60, 75, and 90 minutes com-
pared with the veins (p < 0.05).
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